0001140361-18-030196.txt : 20180627
0001140361-18-030196.hdr.sgml : 20180627
20180627185803
ACCESSION NUMBER: 0001140361-18-030196
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180626
FILED AS OF DATE: 20180627
DATE AS OF CHANGE: 20180627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: THOMPSON PHILLANDAS T.
CENTRAL INDEX KEY: 0001661781
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37977
FILM NUMBER: 18922838
MAIL ADDRESS:
STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC
CENTRAL INDEX KEY: 0001012477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
STREET 2: BALLYCOOLIN
CITY: DUBLIN
STATE: L2
ZIP: 15
BUSINESS PHONE: 636-449-1830
MAIL ADDRESS:
STREET 1: 16640 CHESTERFIELD GROVE ROAD
STREET 2: SUITE 200
CITY: CHESTERFIELD
STATE: MO
ZIP: 63005
FORMER COMPANY:
FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA
DATE OF NAME CHANGE: 19960422
4
1
doc1.xml
FORM 4
X0306
4
2018-06-26
0
0001012477
AVADEL PHARMACEUTICALS PLC
AVDL
0001661781
THOMPSON PHILLANDAS T.
BLOCK 10-1, BLANCHARDSTOWN
CORPORATE PARK, BALLYCOOLIN
DUBLIN
L2
15
IRELAND
0
1
0
0
See Remarks
ADSs
2018-06-26
4
P
0
10000
5.77
A
91000
D
Stock Option (right to buy)
7.36
2023-12-12
ADSs
100000
100000
D
Stock Option (right to buy)
16.3
2024-12-11
ADSs
95000
95000
D
Stock Option (right to buy)
14.35
2025-12-10
ADSs
100000
100000
D
Stock Option (right to buy)
10.4
2026-12-14
ADSs
100000
100000
D
Stock Option (right to buy)
8.95
2027-12-12
ADSs
80000
80000
D
The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the 4th anniversary of the grant date; (b) 20,000 restricted ADSs granted under the "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the 2nd anniversary of the grant date; (c) 18,000 restricted ADSs granted under the "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the 2nd anniversary of the grant date; and (d) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary).
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
Options become exercisable as to 23,750 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Options become exercisable as to 20,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.
Sr. VP, General Counsel and Corporate Secretary.
/s/ Phillandas T. Thompson
2018-06-27